MX2019012570A - Molecula del receptor de interleucina 4/interleucina 13 para uso veterinario. - Google Patents

Molecula del receptor de interleucina 4/interleucina 13 para uso veterinario.

Info

Publication number
MX2019012570A
MX2019012570A MX2019012570A MX2019012570A MX2019012570A MX 2019012570 A MX2019012570 A MX 2019012570A MX 2019012570 A MX2019012570 A MX 2019012570A MX 2019012570 A MX2019012570 A MX 2019012570A MX 2019012570 A MX2019012570 A MX 2019012570A
Authority
MX
Mexico
Prior art keywords
receptor molecule
veterinary use
contiguous polypeptides
il13r
il4r
Prior art date
Application number
MX2019012570A
Other languages
English (en)
Inventor
Jiann Li Shyr
Nguyen Lam
Zhan Hangjun
Qian Fawn
Original Assignee
Kindred Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kindred Biosciences Inc filed Critical Kindred Biosciences Inc
Publication of MX2019012570A publication Critical patent/MX2019012570A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5406—IL-4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5437—IL-13

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Se proporcionan varias modalidades relacionadas con los polipeptidos contiguos de IL13R/IL4R derivados de las especies de animales de compania y que se unen a IL13 y/o IL4; dichos polipeptidos contiguos pueden usarse en metodos para tratar afecciones inducidas por IL13 y/o IL4 en animales de compania, tales como caninos, felinos y equinos.
MX2019012570A 2017-04-21 2018-04-20 Molecula del receptor de interleucina 4/interleucina 13 para uso veterinario. MX2019012570A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762488509P 2017-04-21 2017-04-21
PCT/US2018/028507 WO2018195388A1 (en) 2017-04-21 2018-04-20 Il4/il13 receptor molecule for veterinary use

Publications (1)

Publication Number Publication Date
MX2019012570A true MX2019012570A (es) 2019-12-02

Family

ID=63856393

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012570A MX2019012570A (es) 2017-04-21 2018-04-20 Molecula del receptor de interleucina 4/interleucina 13 para uso veterinario.

Country Status (9)

Country Link
EP (1) EP3612555A4 (es)
JP (2) JP2020517262A (es)
KR (1) KR20200006528A (es)
CN (1) CN110770250A (es)
AU (2) AU2018254542B2 (es)
BR (1) BR112019021812A2 (es)
CA (1) CA3059731A1 (es)
MX (1) MX2019012570A (es)
WO (1) WO2018195388A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3668536A4 (en) * 2017-08-15 2021-05-26 Kindred Biosciences, Inc. VARIANTS OF IGG FC FOR VETERINARY USE
US20210395340A1 (en) * 2018-10-25 2021-12-23 Kindred Biosciences, Inc. IL4/IL13 Receptor Molecule for Veterinary Use
CN116323659A (zh) * 2020-06-12 2023-06-23 北京伟德杰生物科技有限公司 融合多肽

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6428788B1 (en) * 1995-03-15 2002-08-06 Penn State University Compositions and methods for specifically targeting tumors
US6743604B1 (en) * 1996-12-13 2004-06-01 Smithkline Beecham Corporation Substances and their uses
US7083949B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
ES2277460T3 (es) * 1998-12-14 2007-07-01 Genetics Institute, Llc Cadena del receptor de la citoquina.
EP1268794A2 (en) * 2000-04-07 2003-01-02 Heska Corporation Compositions and methods related to canine igg and canine il-13 receptors
LT2805728T (lt) * 2003-12-23 2020-05-25 Genentech, Inc. Nauji anti-il 13 antikūnai ir jų naudojimai
CN1922204A (zh) * 2004-02-27 2007-02-28 瑞泽恩制药公司 Il－4/il－13特异性的多肽和其治疗应用
JP2008504806A (ja) * 2004-02-27 2008-02-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ−４／ｉｌ−１３特異的ポリペプチドおよびその治療上の使用
EP2674440B1 (en) * 2005-12-16 2019-07-03 IBC Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
MX2009005725A (es) * 2006-12-11 2009-08-24 Wyeth Corp Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13.
US20090156421A1 (en) * 2007-11-06 2009-06-18 Wyeth Assays and methods for evaluating multimeric complexes
EP2702069A4 (en) * 2011-04-29 2015-04-29 Janssen Biotech Inc IL4 / IL13 BINDING REPEAT PROTEINS AND USES THEREOF
WO2013087660A1 (en) * 2011-12-13 2013-06-20 Pieris Ag Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
WO2013112871A1 (en) * 2012-01-27 2013-08-01 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic il-13 polypeptides
ES2701093T3 (es) * 2012-08-21 2019-02-20 Sanofi Biotechnology Métodos para tratar o prevenir el asma administrando un antagonista de IL-4R
CA3232651A1 (en) * 2015-04-02 2016-10-06 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
CN114146056A (zh) * 2015-07-29 2022-03-08 纳米提克斯有限责任公司 用于清除可溶性生物分子的模块化组合物及其相关方法

Also Published As

Publication number Publication date
EP3612555A1 (en) 2020-02-26
AU2018254542A1 (en) 2019-11-21
AU2018254542B2 (en) 2022-12-22
EP3612555A4 (en) 2020-12-30
BR112019021812A2 (pt) 2020-05-26
RU2019137211A3 (es) 2021-09-09
CN110770250A (zh) 2020-02-07
CA3059731A1 (en) 2018-10-25
WO2018195388A1 (en) 2018-10-25
RU2019137211A (ru) 2021-05-21
AU2023201726A1 (en) 2023-04-27
JP2023078158A (ja) 2023-06-06
KR20200006528A (ko) 2020-01-20
US20200048325A1 (en) 2020-02-13
JP2020517262A (ja) 2020-06-18

Similar Documents

Publication Publication Date Title
MX2020006668A (es) Anticuerpos para lilrb2.
MX2021004313A (es) Variantes de fc con union alterada al receptor de fc neonatal (fcrn) para uso veterinario.
CY1123236T1 (el) Αντισωματα διπλης εξειδικευσης που δεσμευονται με cd38 και cd3
MY199019A (en) Pd-1 antibodies
NZ739499A (en) Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof
MX2018003689A (es) Proteinas de union a pd-1 y metodos para usarlas.
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
MX2019002867A (es) Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1.
BR112017020054A2 (pt) anticorpos para icos
MY181106A (en) Anti-lag3 antibodies and uses thereof
MX2017014188A (es) Anticuerpos anti-ox40 y metodos para su uso.
MX2018001954A (es) Diacuerpos monovalentes biespecificos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos.
MX2017016811A (es) Metodos para mejorar el rendimiento del animal.
SG10201806108TA (en) Binding proteins and methods of use thereof
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
MX2021011335A (es) Antagonistas de ngf para uso medicinal.
EA201791093A1 (ru) Антитела к cd47, способы и применение
BR112016024515A2 (pt) proteínas do agonista do receptor trail de cadeia única
MX2017016500A (es) Composiciones de pienso para animales y uso de las mismas.
MX2019012570A (es) Molecula del receptor de interleucina 4/interleucina 13 para uso veterinario.
BR112015031719A2 (pt) método para preparar aditivo de ração
MX2021002971A (es) Anticuerpos del receptor anti-interleucina 4 para uso veterinario.
BR112017009976A2 (pt) gado de leite híbrido e sistemas para maximizar vantagem híbrida
MX2016012219A (es) Agonistas de receptor fgf21 y usos del mismo.
PH12019502313A1 (en) Anti-pd-l1-anti-tim-3 bispecific antibodies